Q&A-TriApex

Q: What is TriApex's business and industrial layout?

A: At present, we have set up subsidiaries in Nanjing, Shanghai, Kunming, Hainan and Chengdu, which design Nanjing: non-clinical GLP laboratory facilities, clinical biological sample analysis and detection, medical laboratory, non-clinical medical device laboratory, laboratory animal resources supply chain and rich clinical research center resources.
At the same time, we are also promoting the establishment of a laboratory and commercial office in the United States.

Q: What are the advantages of TriApex in regulatory certification and compliance?

A: We are AAALAC/NMPA/FDA accredited, and also strictly follow OECD/GCP/CNAS/CAP.

Q: What are the customer groups of TriApex and what product areas are involved?

A: We have more than 500 domestic and foreign excellent partners, and have reached in-depth cooperation with the world's TOP20 pharmaceutical companies. Cooperation products include biological products (antibodies, ADCs, peptides, oncolytic viruses, vaccines, cell gene therapy products) and chemicals (innovative chemicals, new drug delivery systems).

Q: In what ways can TriApex's regulatory strategies and registration declaration help drug research and development?

A: Focusing on drug administration strategy, regulatory guidance, registration application and review follow-up, we can rely on the latest drug administration regulations/technical guidelines and interdisciplinary expert consultant team to output competitive development strategies for customers, formulate registration application routes, and conduct pre-review, risk assessment and production of application materials.

Q: How does TriApex help drug development throughout the life cycle?

A: Our service capabilities include early transformation, drug administration strategy output, clinical transformation, communication and application, drug administration consultant, and finally help drugs achieve marketing.

Q: How is TriApex's integrated research and development empowerment in the field of specific diseases reflected?

A: We have a deep understanding of research needs and regulatory requirements in the fields of ophthalmology, central nervous system and metabolism, and rely on advanced technical means and animal resources to provide disease models and pharmacodynamics, pharmacokinetics, non-clinical safety assessment, clinical research and drug administration strategies.